Duke Street Bio announces first patient dosed in Phase I trial with DSB2455, a next deneration PARP1 selective inhibitor for the treatment of solid tumours
December 3, 2024
December 3, 2024
November 27, 2024
November 19, 2024
November 18, 2024
November 14, 2024
November 8, 2024
October 28, 2024
October 9, 2024
October 8, 2024
January 9, 2025
Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmac...
January 8, 2025
Seasoned executive joins PrecisionLife to drive commercial strategy for new first-in-class precision medicine tests to predict and prevent complex, ch...
January 8, 2025
Combining leading hardware and software is expected to provide a compelling solution for digital pathology users across the full translational medicin...
Life Science Newswire is a division of BioStrata Ltd, with company registered address: 3rd Floor, 1 Ashley Road, Altrincham, Cheshire, England, WA14 2DT. Company registration number: 8233225